2011 Focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 29, Issue 28, 2011, Pages 3825-3831

  Azzoli, Christopher G ^a   Temin, Sarah ^b   Aliff, Timothy ^e   Baker Jr , Sherman ^c   Brahmer, Julie ^f   Johnson, David H ^h   Laskin, Janessa L ^j   Masters, Gregory ^k   Milton, Daniel ^l   Nordquist, Luke ^m   Pao, William ⁿ   Pfister, David G ^a   Piantadosi, Steven ^o   Schiller, Joan H ^h   Smith, Reily ^c   Smith, Thomas J ⁱ   Strawn, John R ⁱ   Trent, David ^d   Giaccone, Giuseppe ^g  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d Virginia Cancer Center   (United States)

^e Northwest Oncology and Hematology Associates   (United States)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁱ British Columbia Cancer Agency ^*

^j BRITISH COLUMBIA CANCER AGENCY   (Canada)

^k HELEN F GRAHAM CANCER CENTER   (United States)

^l Nebraska Cancer Specialists   (United States)

^m Nebraska Cancer Specialists   (United States)

ⁿ VANDERBILT INGRAM CANCER CENTER   (United States)

^o Samuel Oschin Comprehensive Cancer Center Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MITOMYCIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; TAXANE DERIVATIVE; VINCA ALKALOID;

ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MEDICAL SOCIETY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80053639884     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.2774     Document Type: Review

References (19)

1. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
2. Keedy VL, Temin S, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 29:2121-2127, 2011
3. Fidias PM, Dakhil SR, Lyss AP, et al: Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27:591-598, 2009
4. Ciuleanu T, Brodowicz T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall- cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374:1432-1440, 2009
5. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11:521-529, 2010
6. Johnson EA, Marks RS, Mandrekar SJ, et al: Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer 60:200-207, 2008 (Pubitemid 351609147)
7. Takeda K, Hida T, Sato T, et al: Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: Results of a West Japan Thoracic Oncology Group trial (WJTOG0203). J Clin Oncol 28:753-760, 2010
8. Perol M, Chouaid C, Milleron B: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 28:540s, 2010 (suppl; abstr 7507)
9. Miller VA, O'Connor P, Soh C: A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27:799s, 2009 (suppl; abstr LBA8002)
10. Kabbinavar FF, Miller VA, Johnson BE: Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 28:544s, 2010 (suppl; abstr 7526)
11. Goldstraw P, Crowley J, Chansky K, et al: The IASLC Lung Cancer Staging Project: Proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumors. J Thorac Oncol 2:706-714, 2007 (Pubitemid 47357522)
12. Scagliotti GV, Parikh P, Von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
13. Fidias P, Novello S: Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:5116-5123, 2010
14. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004 (Pubitemid 41079796)
15. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
16. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
17. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002 (Pubitemid 34438899)
18. Reck M, Von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809, 2010
19. Park JO, Kim SW, Ahn JS, et al: Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol 25:5233-5239, 2007